OSE Immunotherapeutics (OSE):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】OSE Immunotherapeutics (OSE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8310)・商品コード:DATA904C8310
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:47
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
OSE Immunotherapeutics (OSE), formerly OSE Pharma SA is a biotechnology company that discovers and develops immunotherapy products against invasive and metastatic late-stage cancers. The company’s memopi technology is employed in studying the development of treatments for ovarian, colon and breast cancer. It provides products such as tedopi and effi-7. OSE’s Effi-7 is in preclinical development and targets autoimmune diseases and transplantation. OSE’s tedopi stimulates cytotoxic killer T cells and relearns them to detect cancer cells to eliminate them. The company offers pipeline products such as OSE-172, OSE-703, FR104, 0SE-127. It markets its products through its distribution network. OSE is headquartered in Nantes, France.

OSE Immunotherapeutics (OSE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
OSE Immunotherapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
OSE Pharma to Raise USD4.1 Million in Venture Financing Round 12
Partnerships 13
OSE Immunotherapeutics Enters into Agreement with GERCOR 13
OSE Immunotherapeutics Enters into Partnership with Memorial Sloan Kettering Cancer Center 14
Selexis Enters into Agreement with OSE Immunotherapeutics 15
OSE Pharma Partners with Effimune 16
Merger 17
Effimune and OSE Pharma Merge 17
Licensing Agreements 18
Boehringer Ingelheim Enters into Licensing Agreement with OSE Immunotherapeutics 18
OSE Immunotherapeutics Enters into Option Agreement with Inserm Transfert 19
OSE Immunotherapeutics Enters into Licensing Agreement with Selexis for OSE-172 20
OSE Immunotherapeutics Enters into Licensing Agreement with Selexis 21
OSE Immunotherapeutics Enters into Option Licensing Agreement with Les Laboratoires Servier 22
Janssen Biotech Exercises Option for Licensing Agreement with OSE Immunotherapeutics 23
OSE Pharma Enters into Licensing Agreement with RAFA Labs 24
OSE Immunotherapeutics Enters into Licensing Agreement with Selexis for OSE-703 25
Equity Offering 26
OSE Pharma Raises USD23 Million in IPO 26
Acquisition 27
OSE Pharma Acquires OPI, Pharma Company 27
OSE Immunotherapeutics – Key Competitors 28
OSE Immunotherapeutics – Key Employees 29
OSE Immunotherapeutics – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Sep 06, 2018: OSE Immunotherapeutics announces first-half 2018 financial results 31
Mar 28, 2018: OSE Immunotherapeutics: 2017 Annual Results and Clinical Advances of its Proprietary and Partnered Products 33
Sep 07, 2017: OSE Immunotherapeutics Reports on First-Half 2017 Financial Results and Provides Update on Clinical Advances of Its Product Portfolio 35
Corporate Communications 37
Apr 12, 2018: OSE Immunotherapeutics Announces Evolution in Company’s Board of Directors and Management 37
Jan 03, 2018: OSE Immunotherapeutics Announces Appointment of Gerard Tardy as Chairman of Company’s Board of Directors 39
Legal and Regulatory 40
Apr 23, 2018: OSE Immunotherapeutics Receives the Euronext Tech40 Label 40
Product News 41
12/14/2017: OSE Immunotherapeutics Receives a Grant from French Government Program “Fonds Unique Interministeriel” to Explore New Cytotoxic Antibodies 41
Clinical Trials 42
May 07, 2018: OSE Immunotherapeutics Presents New Data on OSE-127 at the American Association of Immunologists (AAI) Annual Meeting May 4-8 2018 in Austin, Texas 42
Dec 19, 2017: OSE Immunotherapeutics Presents New Data Analysis Supporting Continued Development of OSE-127 in Inflammatory Bowel Diseases 43
Jun 21, 2017: OSE Immunotherapeutics Receives Payment of €2.6 Million from Bpifrance After Completion of a New Key Milestone for its Product OSE-127 44
Jun 15, 2017: OSE Immunotherapeutics Presents Positive Preclinical Results and Human Ex Vivo Data for OSE-127 (Effi-7) to Support Next Clinical Applications in Inflammatory Bowel Diseases at the Federation of Clinical Immunology Societies Conference 45
Other Significant Developments 46
Jun 13, 2018: OSE Immunotherapeutics Announces Results of 2018 Annual Shareholder Meeting 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Key Facts, 2017 2
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
OSE Immunotherapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
OSE Immunotherapeutics, Deals By Therapy Area, 2012 to YTD 2018 9
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
OSE Pharma to Raise USD4.1 Million in Venture Financing Round 12
OSE Immunotherapeutics Enters into Agreement with GERCOR 13
OSE Immunotherapeutics Enters into Partnership with Memorial Sloan Kettering Cancer Center 14
Selexis Enters into Agreement with OSE Immunotherapeutics 15
OSE Pharma Partners with Effimune 16
Effimune and OSE Pharma Merge 17
Boehringer Ingelheim Enters into Licensing Agreement with OSE Immunotherapeutics 18
OSE Immunotherapeutics Enters into Option Agreement with Inserm Transfert 19
OSE Immunotherapeutics Enters into Licensing Agreement with Selexis for OSE-172 20
OSE Immunotherapeutics Enters into Licensing Agreement with Selexis 21
OSE Immunotherapeutics Enters into Option Licensing Agreement with Les Laboratoires Servier 22
Janssen Biotech Exercises Option for Licensing Agreement with OSE Immunotherapeutics 23
OSE Pharma Enters into Licensing Agreement with RAFA Labs 24
OSE Immunotherapeutics Enters into Licensing Agreement with Selexis for OSE-703 25
OSE Pharma Raises USD23 Million in IPO 26
OSE Pharma Acquires OPI, Pharma Company 27
OSE Immunotherapeutics, Key Competitors 28
OSE Immunotherapeutics, Key Employees 29
OSE Immunotherapeutics, Other Locations 30
OSE Immunotherapeutics, Subsidiaries 30

List of Figures
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
OSE Immunotherapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[OSE Immunotherapeutics (OSE):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8310)販売に関する免責事項を必ずご確認ください。
★調査レポート[OSE Immunotherapeutics (OSE):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆